Should I buy or sell Harrow Health stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks .

What is Harrow Health's stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for Harrow Health's shares. Their HROW share price targets range from $24.00 to $34.40. On average, they anticipate the company's share price to reach $28.13 in the next year. This suggests a possible upside of 159.3% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts .

How have HROW shares performed in 2024?

Harrow Health's stock was trading at $11.20 at the start of the year. Since then, HROW shares have decreased by 3.1% and is now trading at $10.85. View the best growth stocks for 2024 here .

Are investors shorting Harrow Health?

Harrow Health saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,120,000 shares, an increase of 11.3% from the March 15th total of 5,500,000 shares. Based on an average daily trading volume, of 427,600 shares, the short-interest ratio is currently 14.3 days. View Harrow Health's Short Interest .

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HROW earnings forecast .

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) issued its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.27) EPS for the quarter. The business had revenue of $36.36 million for the quarter, compared to analyst estimates of $37.65 million. Harrow Health had a negative net margin of 18.75% and a negative trailing twelve-month return on equity of 29.48%.

What ETF holds Harrow Health's stock?

Jacob Forward ETF holds 10,538 shares of HROW stock, representing 4.41% of its portfolio.

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health issued an update on its FY 2024 earnings guidance on Friday, March, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $188.7 million.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA) , Aldeyra Therapeutics (ALDX) , OPKO Health (OPK) , QUALCOMM (QCOM) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , CymaBay Therapeutics (CBAY) , VBI Vaccines (VBIV) , Exelixis (EXEL) and Mustang Bio (MBIO) .

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (1.10%) and Woodmont Investment Counsel LLC (0.60%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom . View institutional ownership trends .

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HROW

Harrow Health (HROW) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Free HROW Stock Alerts

$10.85

-0.97 (-8.21%)

(As of 04/18/2024 ET)

Compare

Today's Range: $10.83
▼
$11.87
50-Day Range: $10.18
▼
$13.51
52-Week Range: $7.60
▼
$28.25

Volume: 353,384 shs
Average Volume: 506,542 shs
Market Capitalization: $383.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.13

Get Harrow Health alerts:

Harrow Health MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 159.3% Upside
$28.13 Price Target
Short Interest: Bearish
17.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.05
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$1.23 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.39) to $0.69 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.43 out of 5 stars

Medical Sector

492nd out of 918 stocks

Pharmaceutical Preparations Industry

225th out of 426 stocks

3.5

Analyst's Opinion

Consensus Rating
Harrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Harrow Health has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
17.31% of the outstanding shares of Harrow Health have been sold short.
Short Interest Ratio / Days to Cover
Harrow Health has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Harrow Health has recently increased by 11.27%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Harrow Health does not currently pay a dividend.
Dividend Growth
Harrow Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HROW.

3.4

News and Social Media Coverage

News Sentiment
Harrow Health has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Harrow Health this week, compared to 2 articles on an average week.
Search Interest
13 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Harrow Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harrow Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,233,600.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
13.60% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.76% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Harrow Health are expected to grow in the coming year, from ($0.39) to $0.69 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harrow Health is -14.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harrow Health is -14.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harrow Health has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Harrow Health Stock (NASDAQ:HROW)

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

HROW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HROW Stock News Headlines

March 29, 2024 | insidertrades.com

Opaleye Management Inc. Acquires 50,000 Shares of Harrow Health, Inc. (NASDAQ:HROW) Stock

March 26, 2024 | insidertrades.com

Mark L. Baum Acquires 9,000 Shares of Harrow Health, Inc. (NASDAQ:HROW) Stock

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 23, 2024 | insidertrades.com

Opaleye Management Inc. Acquires 50,600 Shares of Harrow Health, Inc. (NASDAQ:HROW) Stock

April 15, 2024 | americanbankingnews.com

Harrow Health, Inc. (NASDAQ:HROW) Sees Significant Increase in Short Interest

April 13, 2024 | americanbankingnews.com

Harrow Health (NASDAQ:HROW) Coverage Initiated at Craig Hallum

April 3, 2024 | bizjournals.com

Melt Pharmaceuticals raises $24 million for drug development

April 2, 2024 | finance.yahoo.com

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 21, 2024 | finance.yahoo.com

Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript

March 20, 2024 | investorplace.com

Why Is Harrow (HROW) Stock Up 5% Today?

March 20, 2024 | msn.com

Harrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5M

March 19, 2024 | investorplace.com

HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023

March 19, 2024 | finance.yahoo.com

Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023

March 19, 2024 | businesswire.com

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

March 18, 2024 | benzinga.com

Earnings Preview: Harrow Health

March 13, 2024 | finance.yahoo.com

Harrow (HROW) Fell on Lowering the Guidance

March 5, 2024 | finance.yahoo.com

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

February 29, 2024 | finance.yahoo.com

Here’s How Harrow (HROW) Weighed on SRK Capital’s Performance

February 15, 2024 | businesswire.com

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

January 11, 2024 | msn.com

Harrow says dry eye drug Vevye now available in US

January 11, 2024 | finance.yahoo.com

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

January 3, 2024 | bizjournals.com

Harrow Inc. partners with technology companies for dry eye prescription Vevye

December 9, 2023 | markets.businessinsider.com

Harrow Health’s Strong Sales Growth and Strategic Acquisitions Fuel Buy Rating

November 29, 2023 | finance.yahoo.com

Harrow Completes Transfer of the TRIESENCE® New Drug Application

November 24, 2023 | seekingalpha.com

HROWM Harrow Health, Inc. NT CAL 27

November 20, 2023 | finance.yahoo.com

Harrow to Present at Two Investor Conferences in November

See More Headlines

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HROW
CUSIP: N/A
CIK: 1360214
Web: www.harrowinc.com
Phone: (615) 733-4730
Fax: 858-345-1745
Employees: 182
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $28.13
High Stock Price Target: $34.40
Low Stock Price Target: $24.00
Potential Upside/Downside: +159.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,410,000.00
Net Margins: -18.75%
Pretax Margin: -18.21%
Return on Equity: -29.48%
Return on Assets: -5.37%

Debt

Debt-to-Equity Ratio: 2.60
Current Ratio: 2.83
Quick Ratio: 2.61

Sales & Book Value

Annual Sales: $130.19 million
Price / Sales: 2.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.01 per share
Price / Book: 5.40

Miscellaneous

Outstanding Shares: 35,360,000
Free Float: 30,554,000
Market Cap: $383.66 million
Optionable: Optionable
Beta: 0.48

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Mark L. Baum J.D. (Age 49)
CEO & Chairman
Comp: $1.07M
Mr. Andrew R. Boll C.F.A. (Age 40)
C.M.A., CFA, CMA, CFO & Corp. Sec.
Comp: $716.73k
Dr. Robert J. Kammer D.D.S. (Age 73)
Special Advisor
Comp: $91.88k
Mr. John P. Saharek MBA (Age 62)
Chief Commercial Officer
Comp: $621.92k
Jamie Webb
Director of Communications & Investor Relations
Dr. Dennis E Saadeh Pharm.D.
Chief of Formulation Strategy
Mr. Andrew Livingston
Chief Innovation Officer
Ms. Kim Barratt
Chief Talent Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HROW Stock Analysis - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings or view top-rated stocks.
What is Harrow Health's stock price target for 2024?: 2 Wall Street analysts have issued 1-year price objectives for Harrow Health's shares. Their HROW share price targets range from $24.00 to $34.40. On average, they anticipate the company's share price to reach $28.13 in the next year. This suggests a possible upside of 159.3% from the stock's current price.
View analysts price targets for HROW or view top-rated stocks among Wall Street analysts.
How have HROW shares performed in 2024?: Harrow Health's stock was trading at $11.20 at the start of the year. Since then, HROW shares have decreased by 3.1% and is now trading at $10.85.
View the best growth stocks for 2024 here.
Are investors shorting Harrow Health?: Harrow Health saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,120,000 shares, an increase of 11.3% from the March 15th total of 5,500,000 shares. Based on an average daily trading volume, of 427,600 shares, the short-interest ratio is currently 14.3 days.
View Harrow Health's Short Interest.
When is Harrow Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HROW earnings forecast.
How were Harrow Health's earnings last quarter?: Harrow Health, Inc. (NASDAQ:HROW) issued its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.27) EPS for the quarter. The business had revenue of $36.36 million for the quarter, compared to analyst estimates of $37.65 million. Harrow Health had a negative net margin of 18.75% and a negative trailing twelve-month return on equity of 29.48%.

What ETF holds Harrow Health's stock?: Jacob Forward ETF holds 10,538 shares of HROW stock, representing 4.41% of its portfolio.
What guidance has Harrow Health issued on next quarter's earnings?: Harrow Health issued an update on its FY 2024 earnings guidance on Friday, March, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $188.7 million.
What other stocks do shareholders of Harrow Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).
Who are Harrow Health's major shareholders?: Harrow Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (1.10%) and Woodmont Investment Counsel LLC (0.60%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends.
How do I buy shares of Harrow Health?: Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HROW) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Harrow Health (HROW) Stock Price, News & Analysis

Harrow Health MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Harrow Health Stock (NASDAQ:HROW)

HROW Stock Price History

HROW Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

HROW Stock Analysis - Frequently Asked Questions

Overall MarketRank^™